A validated RP-HPLC method for separation and determination of Etoricoxib and Paracetamol in bulk and pharmaceutical dosage form

Abstract

Etoricoxib is a non-steroidal, anti-inflammatory drug (NSAID) and a selective inhibitor of Cyclooxygenase 2 (COX2), which makes it safer on the gastrointestinal tract than the other NSAIDs. Given the importance of Etoricoxib’s, its combination with paracetamol offers higher efficacy and fewer side effects. In addition to the popularity of this combination in the pharmaceutical industry and the diversity of its manufacturing companies